Role of Allo-SCT for CML in 2010

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2010 Jun 10

PMID 20531284

Citations 4

Authors

N Venepalli

K Rezvani

S Mielke

B N Savani

Affiliations

Soon will be listed here.

Abstract

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of CML. However, for a minority of patients who fail TKI or progress to advanced phase disease, allo-SCT remains the only therapeutic option. This review addresses the current indications for allo-SCT in CML and the role of conditioning (myeloablative vs reduced intensity), donor source (sibling vs volunteer unrelated donor), graft source (BM vs peripheral blood vs cord) and the value of pre-, peri- and post transplant use of TKI in the management of CML.

Citing Articles

Effect of graft sources on allogeneic hematopoietic stem cell transplantation outcome in adults with chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a Japanese Society of Hematopoietic Cell Transplantation retrospective analysis.

Ohashi K, Nagamura-Inoue T, Nagamura F, Tojo A, Miyamura K, Mori T Int J Hematol. 2014; 100(3):296-306.

PMID: 25085253 DOI: 10.1007/s12185-014-1632-9.

Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre's experience.

Latif A, McQuaker G, Parker A, Clark A, Copland M Leuk Res Rep. 2013; 2(2):47-50.

PMID: 24371779 PMC: 3850380. DOI: 10.1016/j.lrr.2013.05.001.

Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies.

Abdul Wahid S Int J Hematol. 2013; 97(5):581-98.

PMID: 23585244 DOI: 10.1007/s12185-013-1313-0.

Development of an effective therapy for chronic myelogenous leukemia.

Woessner D, Lim C, Deininger M Cancer J. 2011; 17(6):477-86.

PMID: 22157291 PMC: 3251313. DOI: 10.1097/PPO.0b013e318237e5b7.